Diabetes

23 October 2009

Long-acting insulin better for some

Long-acting insulin works better than other types of injections for people who need more than pills for their type 2 diabetes, researchers report.

0

Long-acting insulin works better than other types of injections for people who need more than pills for their type 2 diabetes, researchers report.

Long-acting Levemir insulin given at bedtime and NovoRapid insulin injections given three times a day before meals controlled insulin levels best in patients not doing well with the daily pills alone, the study found.

They were compared to results with twice-daily injections of NovoMix 30 in diabetes patients taking the pills metformin and sulfonylurea.

Drugmaker Novo Nordisk sponsored the trial of diabetes patients in Britain and Ireland and made all the insulin products tested.

The goal was to bring glycated haemoglobin levels – a measure known as A1C – down to 6.5%. This gives doctors an idea of insulin levels over the long term.

Better weight, better blood-sugar control
Dr Rury Holman of the Oxford Centre for Diabetes, Endocrinology and Metabolism in Britain and colleagues watched their 708 patients for three years.

Most did need extra insulin to control their diabetes – ultimately, 68% to 82% of the patients needed to add a second type of insulin to keep their blood sugar low.

The long-acting insulin helped about 45% of the patients, while only 32% of those who got twice-daily shots of NovoMix 30 controlled their insulin well, the researchers reported in the New England Journal of Medicine.

But the patients who got the three insulin injections a day were more likely to gain weight and more than three times as likely to have an episode where their blood sugar dipped too low, compared to those who took the long-acting insulin, the researchers found.

Potentially dangerous hypoglycaemia incidents were nearly doubled among patients who received the twice-daily injections.

(Reuters Health, October 2009)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.